Genmab (GMAB) said Tuesday that the global net trade sales of Darzalez (daratumumab), as reported by Johnson & Johnson (JNJ), were $3.24 billion in the first quarter.

Genmab receives royalties on the worldwide net sales of Darzalex under the exclusive worldwide license to Johnson & Johnson to develop, manufacture and commercialize daratumumab, the biotechnology company said.

Darzalex net sales also included sales of the subcutaneous product, daratumumab and hyaluronidase-fihj, sold under the tradename Darzalex Faspro in the US, the company said.

Of the total, net trade sales were $1.83 billion in the US and $1.41 billion in the rest of the world, the company said.

Price: 19.44, Change: +0.12, Percent Change: +0.62